3Mathew J, Hines JE, Obafunwa JO, et al. CD44 is expressed in hepatoceUular carcinomas showing vascular invasion. J Pathol, 1996, 179:74-83.
4Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ ezrin complex in cancer metastasis. Crit Rev Oncol Hematol, 2003, 46:165-186.
5Ohtani K, Sakamoto H, Rutherford T, et al. Ezrin, a membranecytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett, 2002, 179:79-86.
6Akisawa N, Nishimori I, Iwamura T, et al. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun, 1999, 258: 395-400.
7Moilanen J, Lassus H, Leminen A, et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol, 2003, 90:273-281.
8Makitie T, Carpen O, Vaheri A, et al. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthahnol Vis Sci, 2001, 42:2442-2449.
9Hefler LA, Concin N, Mincham D, et al. The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a mulficenter study. Cancer, 2002, 94:125-130.
10Sahai E, Marshall CJ. RHO-GTPases and cancer [J]. Nat Rev Cancer, 2002,2(2) : 133-142.
5Bretscher A. Purification of an 80,000-dalton protein that is a com-ponent of the isolate microvillus cytoskeleton,and its localization innon-muscle cells[ J]. J Cell Biol, 1983 ,97(2) :425-432.
6Yu Y,Khan J,Khanna C,et al. Expression profiling identifies thecytoskeletal orgnizer ezrin and the developmental homeoproteinSix-1 as key metastatic regulators [ J]. Nat Med,2004,109 ( 20):175-181.
7Khanna C,Wan X. The membrane-cytoskeleton linker ezrin is nec-essary for osteosarcoma metastasis [ J ] . Nat Med,2004, 10 ( 2 ):182-186.
8Mehrabi A,Mood ZA,Roshanaei N,et al. Mesohepatectomy as anoption for the treatment of central liver tumors [ J ] . J Am Coll Sui^,2008,207(4) :499-509.
